|
2024
|
Invention
|
Novel methods.
The disclosure provides methods for the treatment of Bipolar II Disorder, compris... |
|
|
Invention
|
Organic compound.
The invention relates to pharmaceutical compositions comprising the compound o... |
|
|
Invention
|
Substituted heterocycle fused gamma-carbolines synthesis.
The present invention provides improve... |
|
|
P/S
|
Providing medical information, namely, information regarding medical conditions and treatments to... |
|
|
Invention
|
Novel methods.
The disclosure provides methods for the acute treatment of depression and/or anxi... |
|
|
Invention
|
Pharmaceutical capsules comprising lumateperone mono-tosylate. The present disclosure relates to ... |
|
|
Invention
|
Novel compounds and methods.
The present invention relates to use of particular substituted hete... |
|
|
Invention
|
Novel methods.
The present disclosure relates to pharmaceutical capsules comprising lumateperone... |
|
|
Invention
|
Novel methods.
The present disclosure relates to solid oral dosage forms comprising lumateperone... |
|
|
Invention
|
Lumateperone and derivatives thereof for modulating the nervous system. The present disclosure re... |
|
2023
|
Invention
|
Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor. 2A2A) receptor, in p... |
|
|
Invention
|
Novel methods.
The disclosure provides methods the treatment of psychiatric disorders caused by ... |
|
|
Invention
|
Pharmaceutical capsule compositions comprising lumateperone mono-tosylate. The present disclosure... |
|
|
Invention
|
Organic compounds.
The invention relates to particular substituted heterocycle fused gamma-carbo... |
|
|
Invention
|
Novel uses.
The disclosure provides methods, treatments and materials for enhancing the effect o... |
|
|
Invention
|
Methods. The disclosure provides methods for the treatment of Bipolar II Disorder, comprising adm... |
|
|
Invention
|
Amorphous solid dispersions.
The disclosure provides new, stable, pharmaceutically acceptable am... |
|
|
Invention
|
Methods and compositions for sleep disorders and other disorders.
Use of particular substituted ... |
|
|
Invention
|
Novel methods.
The disclosure provides the use of particular substituted heterocycle fused gamma... |
|
|
Invention
|
Transmucosal methods for treating psychiatric and neurological conditions.
The disclosure provid... |
|
|
Invention
|
Pharmaceutical compositions comprising 4-((6br,10as)-3-methyl2,3,6b,9,10,10a-hexahydro-1h-pyrido[... |
|
|
Invention
|
Pharmaceutical compositions comprising heterocycle fused gamma carboline prodrugs. 2 receptor sig... |
|
|
Invention
|
Novel salts and crystals. The disclosure provides new, stable, crystalline salt forms of lumatepe... |
|
|
Invention
|
Organic compounds.
The invention relates to particular substituted deuterated heterocycle fused ... |
|
|
Invention
|
Organic compounds.
The invention relates to pharmaceutical compositions comprising 4-((6bR,10aS)... |
|
|
Invention
|
Novel methods. 2A2A. |
|
|
Invention
|
Organic compounds. 2A 122 receptor signaling system, and/or the μ-opioid receptor. |
|
|
Invention
|
Organic compounds. 2A 122 receptor signaling system. |
|
|
Invention
|
Organic compounds. The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors alo... |
|
|
Invention
|
Salt crystals. Disclosed herein are acid addition salt and salt crystals of (6aR, 9aS)-5,6a,7,8,9... |
|
|
Invention
|
Novel compositions. The present disclosure relates to amorphous solid dispersions comprising (6aR... |
|
2022
|
Invention
|
Organic compounds.
This invention relates to particular substituted heterocycle fused gamma-carb... |
|
|
Invention
|
Novel methods.
The invention relates to particular substituted heterocycle fused gamma-carboline... |
|
|
Invention
|
Novel methods. The invention relates to particular substituted heterocycle fused gamma-carbolines... |
|
|
Invention
|
Co-crystals.
The present disclosure relates to co-crystals of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-... |
|
|
Invention
|
Novel salts and crystals.
The disclosure provides new salts, crystals and co-crystal forms of pa... |
|
|
P/S
|
Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations for... |
|
|
Invention
|
Salt crystals.
The present disclosure relates to free base and salt crystals of 2-(4-acetylbenzy... |
|
2021
|
Invention
|
Novel salts, crystals, and co-crystals.
The disclosure provides salts and crystal forms of a sub... |
|
|
Invention
|
Organic compounds.
The invention relates to particular substituted (3α,5β-3-hydroxy-pregnan-20-o... |
|
|
Invention
|
Novel uses.
The disclosure provides methods, treatments and materials for treating diseases or d... |
|
|
Invention
|
Free base crystals.
The present invention relates to crystals of (6aR, 9aS)-5,6a,7,8,9,9a-hexahy... |
|
2020
|
Invention
|
Methods of treatment.
The present disclosure relates to inhibitors of phosphodiesterase 1 (PDE1)... |
|
|
Invention
|
Organic compounds. 2 receptor signaling system, and/or the μ-opioid receptor. |
|
|
P/S
|
Business administration of patient pharmaceutical reimbursement programs; business administration... |
|
|
P/S
|
Business administration of patient pharmaceutical reimbursement programs; Business administration... |
|
2019
|
P/S
|
Pharmaceutical preparations acting on the central nervous system |
|
|
P/S
|
Pharmaceutical preparations for the treatment of central nervous system diseases and disorders |
|
2017
|
P/S
|
Pharmaceutical preparations for the treatment of schizophrenia and psychosis, dementia, depressio... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of central nervous system diseases and disorders. |
